Related Experiment Videos
Soft tissue reactions of different biodegradable polylactide implants.
A Prokop1, A Jubel, H J Helling
1Department of Trauma and Reconstructive Surgery, University Hospital, Cologne, Joseph-Stelzmann-Strasse 9, D-50924 Cologne, Germany. axel.prokop@uni-koeln.de
Biomaterials
|October 31, 2003
Summary
Biodegradable polylactide implants show minimal soft tissue reactions over 3 years. Adding beta-tricalcium phosphate (beta-TCP) did not significantly alter these outcomes in sheep bone healing.
Area of Science:
- Biomaterials Science
- Orthopedic Surgery
- Histopathology
Background:
- Biodegradable polylactide implants are used in bone fixation.
- Long-term soft tissue reactions to these implants require further investigation.
- Understanding implant degradation and host response is crucial for clinical application.
Purpose of the Study:
- To evaluate soft tissue reactions around biodegradable polylactide implants over a 3-year period.
- To compare reactions between pure polylactide pins and composite pins containing beta-tricalcium phosphate (beta-TCP).
- To assess histological changes in the synovial membrane and lymph nodes.
Main Methods:
- Osteotomy performed on medial femoral condyle in 36 sheep.
- Implants used: poly-L-DL-lactide pins (70/30) or composite pins (90/10) with 10% beta-TCP.
- Histological examination of synovial membrane and lymph nodes at 3, 18, and 36 months.
Main Results:
- Minor, non-specific synovial membrane reactions observed in the composite pin group at 18 months.
- Varied lymph node reactions in both groups, lacking statistical relevance or clear attribution to implants.
- No clinically relevant inflammation of the joint or lymph nodes was detected in either group.
Conclusions:
- Biodegradable polylactide implants exhibit a slow degradation process with no significant adverse soft tissue reactions.
- The addition of 10% beta-TCP to polylactide pins did not enhance or alter the observed tissue responses.
- These findings suggest favorable biocompatibility of polylactide-based implants for bone fixation over a 3-year period.